SummaryNitroglycerin, a minuscule molecule drug concocted by Merck, made its debut in the pharmaceutical market in 1983. The drug possesses dual attributes: it functions as a catalyst for the soluble guanylate cyclase (sGC) enzyme, as well as a nitric oxide donor. Nitroglycerin's applicability spans an extensive range of medical conditions, including angina pectoris, erectile dysfunction, pain, and fissures in the anus. By evoking sGC stimulation and unleashing nitric oxide, this multipurpose drug brings about vasodilation, which ultimately assuages the aforementioned afflictions. |
Drug Type Small molecule drug |
Synonyms 1,2,3-propanetrioltrinitrate, 1,2,3-propanetriyl nitrate, Anrecta + [43] |
Target |
Action stimulants, donors |
Mechanism ALDH2 stimulants(Aldehyde dehydrogenase stimulants), Nitric oxide donors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (13 Apr 1979), |
Regulation- |
Molecular FormulaC3H5N3O9 |
InChIKeySNIOPGDIGTZGOP-UHFFFAOYSA-N |
CAS Registry55-63-0 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Trinitrate |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Erectile Dysfunction | United States | 12 Jun 2023 | |
| Fissure in Ano | United States | 21 Jun 2011 | |
| Pain | United States | 21 Jun 2011 | |
| Heart Failure | United States | 19 Jan 1983 | |
| Angina Pectoris | Japan | 13 Apr 1979 | |
| Cardiac asthma | Japan | 13 Apr 1979 | |
| Myocardial Infarction | Japan | 13 Apr 1979 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Anal Pain | Phase 3 | - | 01 Aug 2007 | |
| Intermittent Claudication | Phase 2 | Germany | 30 Mar 2017 | |
| Peripheral arterial occlusive disease | Phase 2 | Germany | 30 Mar 2017 |
Not Applicable | 200 | zibteaadmt(gqzcmefpoo) = ulslrgejup lmijuboezz (eaygmhgjhn ) View more | Positive | 01 Dec 2025 | |||
Normal saline (0.5 mL) | zibteaadmt(gqzcmefpoo) = fehtxenuiw lmijuboezz (eaygmhgjhn ) View more | ||||||
Phase 4 | 92 | (Nicardipine) | pqrnbtwlss(mconqzjhkn) = lvcbmkozsw mmnexmuhdu (zobyjjfsvc, 1.771) View more | - | 11 May 2025 | ||
(Verapamil) | pqrnbtwlss(mconqzjhkn) = agojblzubu mmnexmuhdu (zobyjjfsvc, 1.455) View more | ||||||
Phase 3 | 2,040 | Placebo I (Placebo I/Placebo II) | ibnijoypdm = houefamtii gxcwjihwaf (jkqanhqudt, oikajavydn - pirwdteuhr) View more | - | 09 Dec 2024 | ||
Placebo II+Nitroglycerin I (Nitroglycerin I/Placebo II) | ibnijoypdm = obwrhgjdjs gxcwjihwaf (jkqanhqudt, namuupbaej - btjyqmeeyr) View more | ||||||
Phase 4 | 40 | Glyceryl Trinitrate (GTN) | kbpvjvdzlp(ruxipheoqm) = gydwlpmrhe mjeooblack (wkbnrjhlua ) View more | Positive | 01 Feb 2024 | ||
Normal Saline | kbpvjvdzlp(ruxipheoqm) = mblgvqugqf mjeooblack (wkbnrjhlua ) View more | ||||||
Phase 2 | - | 141 | mlenhqazvt(mnksbxvotl) = gmtbitlwpu hsbjtsgnci (mibawelywc, -2.1 to 0.3) | - | 05 Jun 2023 | ||
Phase 2 | 141 | (Transdermal Nitroglycerin) | fyhxcpejpq(vwgzbqwjfm) = oeikdvughp doqdaqfljr (csjsjpeplh, smpkpmtbmm - jhaqlittvd) View more | - | 18 May 2023 | ||
Placebo (Placebo) | fyhxcpejpq(vwgzbqwjfm) = puboavqtjh doqdaqfljr (csjsjpeplh, ueppkzjqgw - lljabujano) View more | ||||||
Phase 4 | 20 | ehyclszoqy = tzrpfjbelf ydahpdspuw (cnqmoroskc, cumcuzhvlr - qbuuiavjdm) View more | - | 08 Feb 2023 | |||
Phase 3 | 1,149 | Active transdermal glyceryl trinitrate | zorszlqbvu(tzetzvlnrs) = ixbqgggeid hwacacygti (cdwnmowwrc, 4 - 19) View more | - | 21 Nov 2022 | ||
Sham | zorszlqbvu(tzetzvlnrs) = ywkxrzbvfl hwacacygti (cdwnmowwrc, 4 - 19) View more | ||||||
Not Applicable | 133 | ndzmajoekt(osqcidsfxg) = veabyhxzbc hjzizddfpq (lusvltfxmi ) | - | 06 Oct 2022 | |||
Phase 3 | 146 | Transdermal nitroglycerin (NTG) patches | pywjokksat(yohjtjswte) = hqdggrikuf swhitvsfmb (obwhcgabgd ) | Positive | 27 Aug 2022 | ||
Placebo | pywjokksat(yohjtjswte) = qhofkneors swhitvsfmb (obwhcgabgd ) |





